Safety and tolerability of lamotrigine: Results from 12 placebo-controlled clinical trials and clinical implications

Clinical Neuropharmacology

Volumn 34, Issue 1, 2011, Pages 39-47

  Seo, Ho Jun ^a   Chiesa, Alberto ^b   Lee, Soo Jung ^a   Patkar, Ashwin A ^c   Han, Changsu ^d   Masand, Prakash S ^c   Serretti, Alessandro ^b   Pae, Chi Un ^a,d  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Korea University College of Medicine   (South Korea)

Author keywords

lamotrigine; safety; tolerability

Indexed keywords

LAMOTRIGINE; LITHIUM; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; BACKACHE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL PRACTICE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; HEADACHE; HUMAN; INFECTION; INFLUENZA; INSOMNIA; MANIA; MONOTHERAPY; MOOD DISORDER; NAUSEA; PAIN; POPULATION RESEARCH; PREGNANCY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEDATION; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYNCOPE; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; EXANTHEMA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEVENS-JOHNSON SYNDROME; TRIAZINES;

EID: 79551584480     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182055c07     Document Type: Review

References (58)

1. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392-400.
2. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013-1024.
3. van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-231.
4. Glaxo Smith Kline. Glaxo Smith Kline Study, SCA30924 2006.
5. Glaxo Smith Kline. Glaxo Smith Kline Study SCA40910. 2005.
6. Glaxo Smith Kline. Glaxo Smith Kline Study, SCA100223. 2006.
7. Glaxo Smith Kline. Glaxo Smith Kline Study, SCAA2008. 2005.
8. Glaxo Smith Kline. Glaxo Smith Kline Study SCAA2010. 2005.
9. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61(11):841-850.
10. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60(2):79-88.
11. Glaxo Smith Kline. Glaxo Smith Kline Study, SCAB 2005. 2005.
12. Glaxo Smith Kline. Glaxo Smith Kline Study, SCAB 2009. 2005.
13. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management J Clin Psychiatry 2002;63(11):1012-1019.
14. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40(7):985-991.
15. Naisbitt DJ, Williams DP, Pirmohamed M, et al. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 2001;1(4):317-325.
16. Gaeta F, Alonzi C, Valluzzi RL, et al. Hypersensitivity to lamotrigine and nonaromatic anticonvulsant drugs: a review. Curr Pharm Des 2008;14(27):2874-2882.
17. Maggs JL, Naisbitt DJ, Tettey JN, et al. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000;13(11):1075-1081.
18. Anderson GD, Gidal BE, Messenheimer JA, et al. Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 2002;49(3):211-217.
19. Lu W, Uetrecht JP Possible bioactivation pathways of lamotrigine. Drug Metab Dispos 2007;35(7):1050-1056.
20. Manasco P, Mullens L, Matsuo F. Skin rash associated with Lamictal: incidence, time to onset and risk factors. Epilepsia 1996; 37(suppl 5):S164.
21. Brodie M. Lamotrigine monotherapy: an overview. In: Loiseau P, ed. Lamotrigine a Brighter Future. International Congress and Symposium Series 214. London, UK: Royal Society of Medicine Press.
22. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26(3):423-432.
23. Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf2004;27(3):173-184.
24. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000;55(4):588-591.
25. Weintraub D, Buchsbaum R, Resor SR Jr, et al. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 2005;62(9):1432-1436.
26. Glaxo Smith Kline. Prescribing information: Lamictal (lamotrigine) [online]. Available at: http://us.gsk.com/products/assets/us-lamictal.pdf Accessed April 15 2010.
27. Manfredi G, Pacchiarotti I, Kotzalidis GD, et al. Successful rechallenge with slowly titrated lamotrigine after rash. Bipolar Disord 2004;6(4): 338-339.
28. Buzan RD, Dubovsky SL. Recurrence of lamotrigine-associated rash with rechallenge. J Clin Psychiatry 1998;59(2):87.
29. Aiken CB, Orr C Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont) 2010;7(5):27-32.
30. Codrea Tigaran PS, Sidenius P, Dam M. Lamotrigine-induced rash-worth a rechallenge. Acta Neurol Scand 2005;111(3):191-194.
31. Tavernor SJ, Wong IC, Newton R, et al. Rechallenge with lamotrigine after initial rash. Seizure 1995;4(1):67-71.
32. Huang CW, Tsai JJ, Lai ML. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci 2002;18(11):566-572.
33. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000;9(4):282-286.
34. Biton V Effect of antiepileptic drugs on bodyweight: overview and clinical implications forthe treatment of epilepsy. CNSDrugs 2003;17(11):781-791.
35. Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009;26(3):281-294.
36. Viguera AC, Koukopoulos A, Muzina DJ, et al. Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. J Clin Psychiatry 2007;68(suppl 9):29-33.
37. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77(2):193-198.
38. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998;25(4):S14-S18.
39. Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999;53(8):1724-1731.
40. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. NEngl J Med 1997;337(25):1807-1812.
41. Ueberall MA. Normal growth during lamotrigine monotherapy in pediatric epilepsy patients-a prospective evaluation of 103 children and adolescents. Epilepsy Res 2001;46(1):63-67.
42. Pavuluri MN, Henry DB, Moss M, et al. Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009;19(1):75-82.
43. Biederman J, Joshi G, Mick E, et al. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 16(2):91-102.
44. Sajatovic M, Ramsay E, Nanry K, et al. Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. Int J Geriatr Psychiatry 2007;22(10):945-950.
45. Giorgi L, Gomez G, O'Neill F, et al. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001;18(8):621-630.
46. Robillard M, Conn DK. Lamotrigine use in geriatric patients with bipolar depression. Can JPsychiatry 2002;47(8):767-770.
47. Sajatovic M, Gyulai L, Calabrese JR, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry 2005;13(4):305-311.
48. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42(5):535-541.
49. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60(2):145-156.
50. Besag FM, Berry DJ, Pool F Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. Epilepsia 2000;41(5):624-627.
51. Ebert U, Thong NQ, OertelR, et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000;56(4):299-304.
52. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999;21(2):175-181.
53. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996;31(4):309-324.
54. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61(4):570-571.
55. Information: P. Prescribing information: Lamictal? (lamotrigine) [online]. Available at: http://us.gsk.com/products/assets/us-lamictal.pdf Accessed June 25 2003.
56. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7(2):163-165.
57. Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine. Am J Psychiatry 2001;158(11):1930.
58. Gidal BE, Rutecki P, Shaw R, et al. Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res 1997;28(3):207-211.